Dacarbazine: profile and news
International Approvals: Alertec, Multiferon, Alvesco Feb 27, 2006
...for a natural human alpha-interferon injection, allowing its use for the adjuvant treatment of high-risk melanoma after excision and dacarbazine therapy; and ... - Medscape (subscription)
Neoadjuvant Chemotherapy and Radiotherapy Promising for Large Soft ... Mar 3, 2006
All were scheduled to receive neoadjuvant concomitant radiotherapy and chemotherapy with MAID (mesna, ifosfamide, doxorubicin and dacarbazine). ... - Cancer Consultants (press release),
Viragen's Multiferon Approved in Sweden for First-Line Adjuvant ... Feb 21, 2006
...natural human alpha interferon) for the first-line adjuvant treatment of high-risk (Stages IIb- III) malignant melanoma following dacarbazine (DTIC) after ... - DG News
Viragen's Multiferon approved in Sweden Feb 22, 2006
...regulators have approved Viragen's Multiferon for the first-line adjuvant treatment of high-risk malignant melanoma following dacarbazine after surgical ... - Pharmaceutical Business Review
Neoadjuvant Sarcoma Chemotherapy Results in High Toxicity Levels Mar 1, 2006
The patients received three cycles of neoadjuvant modified mesna, doxorubicin, ifosfamide and dacarbazine (MAID), interdigitated radiotherapy and following ... - Cancerpage.com,
Bilateral adrenal masses: phaeochromocytoma or melanoma? Feb 28, 2006
Despite replacement steroids and a course of palliative dacarbazine chemotherapy, the patient died 9 months after first detection of the adrenal masses. ... - Journal of the Royal Society of Medicine
Genasense(R) New Drug Application Accepted for Review by FDA Mar 1, 2006
Genta has also filed a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - Yahoo! News (press release)
Randomized Trial Shows Ganite(R) Effective When Compared with a ... Mar 2, 2006
Genta has also submitted a Marketing Authorization Application to the European Medicines Agency (EMEA) for use of Genasense plus dacarbazine for treatment of ... - PR Newswire (press release),
Metastatic Melanoma Responds to Taxol® and Paraplatin® Feb 16, 2006
Metastatic melanoma responds poorly to chemotherapy with the main drugs being temozolomide or dacarbazine after failure of immunotherapy or vaccination. ... - Cancer Consultants (press release),
Results show Genta's cancer drug is effective Feb 3, 2006
The phase III study randomly assigned 771 patients to receive standard chemotherapy using dacarbazine with or without Genasense (oblimersen). ... - Pharmaceutical Business Review
Patients With Newly Diagnosed Glioblastoma Multiforme - Health ... Feb 6, 2006
TEMODAR Capsules are contraindicated in patients who have a history of hypersensitivity to any of its components, or to dacarbazine (DTIC). ... - Medical News Today (press release),
International Approvals: Cubicin and Temodal Feb 6, 2006
Temozolomide is contraindicated in patients with a history of hypersensitivity to dacarbazine and should be used with caution in those with severe hepatic or ... - Medscape (subscription)
Genasense(R) Marketing Authorization Application in Melanoma ... Feb 1, 2006
The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, particularly for patients for ... - PR Newswire (press release),
Analysis of Genasense(R) Trial Confirms Major Efficacy Variables ... Feb 2, 2006
...randomized trial ever conducted in patients with advanced melanoma -- randomly assigned 771 patients to receive standard chemotherapy using dacarbazine with or ... - PR Newswire (press release),
Garden State Business Briefs Feb 2, 2006
The clinical trial involved 771 patients with advanced melanoma. Some were given treatment with Genasense and dacarbazine, an intravenous form of chemotherapy. ... - Newark Star Ledger,
Highlights of rising and falling US stocks Feb 2, 2006
The application proposes the use of Genasense plus dacarbazine for treatment of patients with advanced metastatic melanoma, the Berkeley Heights, NJ-based ... - Investor's Business Daily (subscription)
Other information
Indication
For the treatment of metastatic malignant melanoma. In addition, DTIC-Dome is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents
Pharmacology
After intravenous administration of DTIC-Dome, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations DTIC is not appreciably bound to human plasma protein.
Mechanism Of Action
Possibly blocking the formation of inosinic acid.
Drug Category
Antineoplastic Agents; ATC:L01AX04
Brand Names/Synonyms
Biocarbazine R; DIC; DTIC; DTIE; Dacarbazine; Dacarbazino [Inn-Spanish]; Dacarbazinum [Inn-Latin]; Deticene; Dimethyltriazenoimidazolecarboxamide; Dtic-Dome; ICDMT; ICDT; Imidazole Carboxamide
Dosage Forms
LIQUID; POWDER FOR SOLUTION
Absorption
Erratic, slow and incomplete
Interactions
Interactions for Dacarbazine:
No Information Provided.
Chemical IUPAC Name
5-dimethylaminoazo-3H-imidazole-4-carboxamide
Chemical Formula
C6H10N6O
Half Life
5 hours
Drug Type
Approved Drug
# Accession No
APRD00331
CAS Registry Number
3/4/4342